|
|
Article: CombinatoRx and Cystic Fibrosis Foundation Therapeutics Enter into a Collaboration to Develop Novel Therapeutics Built from Synergistic Drug Combinations.
- Article from:
- Business Wire
- Article date:
- June 1, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass. and BETHESDA, Md. -- CombinatoRx, Incorporated (NASDAQ: CRXX) and Cystic Fibrosis Foundation Therapeutics (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, today announced that they have entered into a collaboration to discover and develop novel therapeutics built from synergistic drug combinations to treat cystic fibrosis (CF). Under the terms of the agreement, CFFT will award CombinatoRx up to $13.8 million in research expenses and will also fund up to 75% of clinical development expenses through Phase 2a on the first potential product candidate, provided both parties agree to commence clinical development. ...